Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study Meeting Abstract
| Authors: | Vogel, A.; Chan, S.; Furuse, J.; Tak, W.; Masi, G.; Varela, M.; Kim, J.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; Makowsky, M.; Marcovitz, M.; Negro, A.; Abou-Alfa, G. |
| Abstract Title: | Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study |
| Meeting Title: | ESMO 24th World Congress on Gastrointestinal Cancer 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2022 Jun 29-Jul 2 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-06-01 |
| Start Page: | S380 |
| End Page: | S381 |
| Language: | English |
| ACCESSION: | WOS:000823826500369 |
| DOI: | 10.1016/j.annonc.2022.04.446 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: O-5 -- Source: Wos |
